TABLE 1.

Infection and Case Prevalence by Screening Scenario, Level^*, and Race

Site	Level	(1) Increase Both Rectal/Pharyngeal Screening		(2) Increase Only Rectal Screening		(3) Increase Only Pharyngeal Screening
		Black MSM	White MSM	Black MSM	White MSM	Black MSM	White MSM
Infections: mean (95% CI)
Urogenital	37.5%†	3.0 (3.0–3.1)	1.4 (1.3–1.4)	3.0 (3.0–3.1)	1.4 (1.3–1.4)	3.0 (3.0–3.1)	1.4 (1.3–1.4)
	60%	2.5 (2.5–2.6)	1.1 (1.0–1.1)	2.6 (2.5–2.7)	1.1 (1.1–1.2)	2.8 (2.7–2.8)	1.2 (1.2–1.3)
	80%	2.1 (2.0–2.1)	0.9 (0.8–0.9)	2.3 (2.2–2.4)	1.0 (0.9–1.0)	2.6 (2.5–2.6)	1.1 (1.1–1.2)
	100%	1.8 (1.7–1.9)	0.7 (0.7–0.8)	2.0 (1.9–2.1)	0.8 (0.8–0.9)	2.4 (2.3–2.5)	1.0 (1.0–1.0)
Rectal	37.5%†	6.1 (6.0–6.3)	3.2 (3.1–3.3)	6.1 (6.0–6.3)	3.2 (3.1–3.3)	6.1 (6.0–6.3)	3.2 (3.1–3.3)
	60%	5.0 (4.9–5.2)	2.4 (2.4–2.5)	5.2 (5.1–5.3)	2.6 (2.5–2.7)	5.6 (5.5–5.7)	2.9 (2.8–2.9)
	80%	4.1 (4.0–4.2)	1.9 (1.9–2.0)	4.6 (4.4–4.7)	2.1 (2.1–2.2)	5.2 (5.0–5.3)	2.6 (2.5–2.7)
	100%	3.5 (3.4–3.7)	1.6 (1.5–1.7)	3.9 (3.8–4.0)	1.8 (1.8–1.9)	4.8 (4.7–4.9)	2.3 (2.2–2.4)
Pharyngeal	37.5%†	7.3 (7.1–7.4)	4.1 (4.0–4.2)	7.3 (7.1–7.4)	4.1 (4.0–4.2)	7.3 (7.1–7.4)	4.1 (4.0–4.2)
	60%	6.0 (5.9–6.2)	3.2 (3.1–3.3)	6.3 (6.2–6.5)	3.5 (3.4–3.6)	6.6 (6.4–6.7)	3.7 (3.6–3.8)
	80%	4.9 (4.8–5.0)	2.5 (2.5–2.6)	5.6 (5.5–5.8)	2.9 (2.8–3.0)	6.0 (5.9–6.1)	3.3 (3.2–3.4)
	100%	4.2 (4.1–4.4)	2.1 (2.0–2.2)	4.9 (4.7–5.0)	2.6 (2.5–2.6)	5.5 (5.4–5.7)	2.9 (2.8–3.0)
Cases: mean (95% CI)
Overall	37.5% b	12.8 (12.5–13.0)	7.0 (6.9–7.2)	12.8 (12.5–13.0)	7.0 (6.9–7.2)	12.8 (12.5–13.0)	7.0 (6.9–7.2)
	60%	10.6 (10.3–10.8)	5.4 (5.3–5.6)	11.0 (10.7–11.2)	5.9 (5.7–6.0)	11.6 (11.3–11.8)	6.3 (6.1–6.4)
	80%	8.6 (8.4–8.9)	4.3 (4.2–4.5)	9.7 (9.5–10.0)	4.9 (4.8–5.0)	10.7 (10.4–10.9)	5.7 (5.5–5.8)
	100%	7.4 (7.2–7.7)	3.6 (3.5–3.7)	8.4 (8.2–8.6)	4.2 (4.1–4.4)	9.9 (9.6–10.1)	5.0 (4.9–5.2)

^*Extragenital screening level among men already being urogenitally screened.

^†37.5% is the baseline screening level.